Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
RenovoRx ( (RNXT) ) has issued an announcement.
RenovoRx reported its first quarter 2025 financial results, highlighting $200,000 in revenue from RenovoCath sales, surpassing expectations. The company anticipates continued growth with new and repeat purchase orders. With $14.6 million in cash, RenovoRx plans to fund the commercialization scale-up of RenovoCath and progress its Phase III TIGeR-PaC clinical trial, which is on track for full enrollment in 2025. The trial has seen significant developments, including the addition of Johns Hopkins Medicine as an enrollment site, and is expected to complete its second interim analysis in the third quarter of 2025. RenovoRx’s strategic focus on commercialization and clinical progress positions it for potential market expansion and increased stakeholder value.
The most recent analyst rating on (RNXT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.
RenovoRx’s overall stock score reflects significant financial instability with persistent losses and negative cash flows. Despite technical analysis suggesting some short-term upward momentum, the company’s valuation is weakened by a negative P/E ratio and lack of profitability. The absence of earnings call data and corporate events limits further insights into potential improvements, maintaining a cautious outlook on its stock performance.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
RenovoRx, Inc. is a life sciences company focused on developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel FDA-cleared drug-delivery device. The company operates within the healthcare industry, specifically targeting oncology, and is known for its patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform.
Average Trading Volume: 102,569
Technical Sentiment Signal: Sell
Current Market Cap: $37.65M
See more insights into RNXT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue